BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair. Ms. Reeve brings to Cardurion more […]
Other News
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
MILPITAS, Calif.–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive cardiovascular technologies, announced submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) for the approval of the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease (CAD). DynamX coronary bioadaptor was developed to overcome the limitations of drug-eluting stents (DES) and […]
Promaxo Receives Direct Investment from Surgical Robotics Industry Pioneer Fred Moll and Announces Appointment as Strategic Advisor
OAKLAND, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today that it has received a direct investment from Fred Moll, M.D., industry pioneer and leader in surgical robotics and minimally invasive surgery, with more than 40 years of […]
Shockwave Medical to Livestream 2023 Investor Innovation Day
SANTA CLARA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, will host an Investor Innovation Day on Monday, October 23, 2023, from 1:00 p.m to 4:00 p.m. Pacific Time. The Shockwave Investor […]
Avertix and BIOS Acquisition Corporation Mutually Agree to Terminate Proposed Business Combination
EATONTOWN, N.J. and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and BIOS Acquisition Corporation […]
FineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study
BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a medical device company developing innovative devices for cardiology announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single center, First in Human Study to evaluate the […]
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
TEL AVIV, Israel and MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime […]
SS Innovations Launches Innovative Robotic Cardiac Surgery Program in India
FORT LAUDERDALE, FL, Oct. 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announces the launch of an innovative robotic cardiac surgery program […]
Akura Medical, a Shifamed Portfolio Company, Closes $35M in Series B Financing
LOS GATOS, Calif., October 3, 2023 – Akura Medical, a Shifamed portfolio company focused on a differentiated approach to effectively address the major challenges of venous thromboembolism (VTE), announced today the closing of its $35M Series B financing. The funds will be used to apply for FDA 510(k) clearance for the […]
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced a collaboration with CardioNXT, to support Pulse Biosciences’ planned nsPFA cardiac catheter first-in-human study focused on the […]



